Protocol Ledger

NCT06274801 · Phase III · RECRUITING

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Interventional Phase III clinical trial protocol NCT06274801 sponsored by Gossamer Bio USA in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-03 Enrollment: 330 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06274801
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)330 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06274801
Protocol FieldVerified Registry Value
NCT IdentifierNCT06274801
Consolidated Lead SponsorGossamer Bio USA
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment330 participants (ESTIMATED)
Registered Start Date2024-09-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI